文献速递淋巴瘤

Loncastuximab tesirine治疗复发/难治性B细胞非霍奇金淋巴瘤的1期研究最终结果

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
PubMed 文献 · Blood · 2021-01-01

该1期剂量递增和剂量扩展研究纳入183例复发/难治性B细胞非霍奇金淋巴瘤患者,评估Loncastuximab tesirine(抗CD19抗体药物偶联物)的安全性、临床活性、药代动力学和免疫原性。未达到最大耐受剂量,但200 µg/kg累积毒性更高。可评估患者总缓解率为45.6%,完全缓解率26.7%。

要点

  • 推荐2期剂量为150 µg/kg每3周共2次,随后75 µg/kg每3周。
  • 可评估患者总缓解率45.6%,完全缓解率26.7%。
  • DLBCL、套细胞淋巴瘤和滤泡性淋巴瘤的ORR分别为42.3%、46.7%和78.6%。

核心结论

  • Loncastuximab tesirine在复发/难治性B细胞非霍奇金淋巴瘤中具有显著抗肿瘤活性和可接受的安全性,值得继续研究。

研究设计与样本

  • 1期剂量递增和剂量扩展研究,纳入183例复发/难治性B细胞非霍奇金淋巴瘤患者。
  • 剂量递增采用3+3设计,范围15至200 µg/kg;剂量扩展采用120和150 µg/kg。

主要发现

  • 4例患者报告剂量限制性毒性,均为血液学毒性。
  • 未达到最大耐受剂量,但200 µg/kg累积毒性更高。
  • 可评估患者总缓解率为45.6%,完全缓解率为26.7%。
  • DLBCL、套细胞淋巴瘤和滤泡性淋巴瘤的ORR分别为42.3%、46.7%和78.6%。
  • 所有患者中位缓解持续时间为5.4个月,达到完全缓解的DLBCL患者(剂量≥120 µg/kg)中位缓解持续时间未达到。

关键数值与推荐

  • 2期推荐剂量为150 µg/kg每3周共2次,随后75 µg/kg每3周。
  • 剂量限制性毒性均为血液学毒性,发生于4例患者。

临床怎么用

  • Loncastuximab tesirine可用于复发/难治性B细胞非霍奇金淋巴瘤,推荐2期剂量为150 µg/kg每3周共2次后改为75 µg/kg每3周。
  • 治疗期间需监测血液学毒性及其他常见不良事件如疲劳、恶心、水肿和肝酶异常。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prognosis for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains poor, with a need for alternatives to current salvage therapies. Loncastuximab tesirine (ADCT-402) is an antibody-drug conjugate comprising a humanized anti-CD19 monoclonal antibody conjugated to a pyrrolobenzodiazepine dimer toxin. Presented here are final results of a phase 1 dose-escalation and dose-expansion study in patients with R/R B-NHL. Objectives were to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion and evaluate safety, clinical activity, pharmacokinetics, and immunogenicity of loncastuximab tesirine. Overall, 183 patients received loncastuximab tesirine, with 3 + 3 dose escalation at 15 to 200 µg/kg and dose expansion at 120 and 150 µg/kg. Dose-limiting toxicities (all hematologic) were reported in 4 patients. The MTD was not reached, although cumulative toxicity was higher at 200 µg/kg. Hematologic treatment-emergent adverse events were most common, followed by fatigue, nausea, edema, and liver enzyme abnormalities. Overall response rate (ORR) in evaluable patients was 45.6%, including 26.7% complete responses (CRs). ORRs in patients with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, and follicular lymphoma were 42.3%, 46.7%, and 78.6%, respectively. Median duration of response in all patients was 5.4 months and not reached in patients with DLBCL (doses ≥120 µg/kg) who achieved a CR. Loncastuximab tesirine had good stability in serum, notable antitumor activity, and an acceptable safety profile, warranting continued study in B-NHL. The recommended dose for phase 2 was determined as 150 µg/kg every 3 weeks for 2 doses followed by 75 µg/kg every 3 weeks. This trial was registered at www.clinicaltrials.gov as #NCT02669017.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021. PMID: 33211842. doi:10.1182/blood.2020007512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。